News REGENXBIO Inc.

Equities

RGNX

US75901B1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
17.5 ^USD	-2.89%		-7.94%	-2.51%

Mar. 28	REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD	CI
Mar. 18	Transcript : REGENXBIO Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 03:30 PM

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

REGENXBIO And Sarepta Agree To Stay Litigation Pending Outcome Of Sarepta's IPR Petition	Apr. 04	AQ
One-time gene therapy could improve wet AMD	Apr. 01	AQ
REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD	Mar. 28	CI
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days	Mar. 27	PR
Transcript : REGENXBIO Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 03:30 PM	Mar. 18
Transcript : REGENXBIO Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 through Mar-14-2024	Mar. 13
HC Wainwright Initiates REGENXBIO With Buy Rating, $36 Price Target	Mar. 11	MT
REGENXBIO to Participate in Upcoming Investor Conferences	Mar. 11	PR
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
Regenxbio Insider Sold Shares Worth $365,220, According to a Recent SEC Filing	Mar. 08	MT
RBC Upgrades REGENXBIO to Outperform From Sector Perform, Lifts Price Target to $35 From $20, 'Impressed by Recent Execution,' Keeps Speculative Risk	Mar. 08	MT
REGENXBIO Announces Proposed Public Offering of Common Stock	Mar. 07	AQ
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
Regenxbio Plans to Sell $125 Million in Equity Offering	Mar. 06	MT
Leerink Partners Upgrades REGENXBIO to Outperform From Market Perform	Mar. 06	MT
Baird Adjusts Price Target on REGENXBIO to $39 From $34, Maintains Outperform Rating	Mar. 06	MT
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE TRIAL	Mar. 06	AQ
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Mar. 05	MT
Sector Update: Health Care	Mar. 05	MT
Regenxbio Reports Higher Microdystrophin Expression in Phase 1/2 Duchenne Study	Mar. 05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News REGENXBIO Inc.

Equities

RGNX

US75901B1070

Summary

Filters